TP53 and adenocarcinoma: They found that TP53 was the dominant mutation seen in adenocarcinoma, in over 80 per cent of samples, but that these mutations were also present in biopsies from never‐dysplastic patients, contrary to what was expected based on the known oncological progression of these lesions.